CHMP4B: A Potential Drug Target for Various Diseases (G128866)

Target Name: CHMP4B

NCBI ID: G128866

CHMP4B

CHMP4B: A Potential Drug Target for Various Diseases

Chromatin modifying protein 4B (CHMP4B) is a protein that plays a critical role in the regulation of chromatin structure and gene expression. It is a key player in the epigenetic landscape, helping to modify the accessibility and composition of chromatin. CHMP4B is also involved in the regulation of cellular processes such as cell growth, apoptosis, and DNA damage repair.

Due to its involvement in these critical cellular processes, CHMP4B has been identified as a potential drug target. Researchers are currently exploring the use of small molecules and other compounds to modulate CHMP4B activity and treat various diseases. In this article, we will explore the biology of CHMP4B, its role in disease, and the potential for CHMP4B-based therapeutics.

The biology of CHMP4B

CHMP4B is a 21-kDa protein that is expressed in various tissues throughout the body. It is highly conserved, with a calculated pI of 12.9 and a predicted localization in the nucleosome. CHMP4B is a component of the nucleosome, which is the basic unit of chromatin that consists of a core DNA molecule and a surrounding protein complex.

CHMP4B functions as a chromatin modifier by modifying the accessibility and composition of chromatin. It does this by interacting with the nucleosome complex and modifying the histone modifications on the tips of the histone tails. These modifications include acetylation and methylation, which are involved in the regulation of gene expression.

CHMP4B is also involved in the regulation of cellular processes such as cell growth, apoptosis, and DNA damage repair. It has been shown to play a role in the regulation of cell cycle progression, with studies suggesting that it may be involved in the G1/ S transition. CHMP4B has also been shown to be involved in the regulation of apoptosis, with studies suggesting that it may be a negative regulator of cell death.

The potential for CHMP4B-based therapeutics

The potential for CHMP4B-based therapeutics is high, given the critical role that CHMP4B plays in various cellular processes. Currently, there are several compounds that are being explored as potential CHMP4B inhibitors. These compounds include small molecules, such as 4-fluorouracil, which is a commonly used inhibitor of DNA polymerase, and macrolide antibiotics, such as tetracycline and clindamycin.

Another approach to targeting CHMP4B is to use RNA interference (RNAi) technology. RNAi is a technique that involves the use of small interfering RNA (siRNA) to knockdown the expression of specific genes. By using RNAi to knockdown the expression of CHMP4B, researchers can reduce the activity of this protein and potentially treat various diseases.

Another approach to targeting CHMP4B is to use protein-interference technology. This technology involves the use of antibodies to target specific proteins and then use them to block their activity. By using protein-interference technology to target CHMP4B, researchers can also potentially treat various diseases.

CHMP4B-based therapeutics for diseases

CHMP4B plays a critical role in the regulation of various diseases, and targeting its activity may be a promising approach to treating these diseases.

1. Cancer: CHMP4B has been shown to play a critical role in the regulation of cancer cell growth and survival. Several studies have suggested that CHMP4B inhibitors may be an effective treatment for various types of cancer, including breast, lung, and ovarian cancer.
2. Genetic disorders: CHMP4B is involved in the regulation of various genetic processes, including DNA

Protein Name: Charged Multivesicular Body Protein 4B

Functions: Probable core component of the endosomal sorting required for transport complex III (ESCRT-III) which is involved in multivesicular bodies (MVBs) formation and sorting of endosomal cargo proteins into MVBs. MVBs contain intraluminal vesicles (ILVs) that are generated by invagination and scission from the limiting membrane of the endosome and mostly are delivered to lysosomes enabling degradation of membrane proteins, such as stimulated growth factor receptors, lysosomal enzymes and lipids. The MVB pathway appears to require the sequential function of ESCRT-O, -I,-II and -III complexes. ESCRT-III proteins mostly dissociate from the invaginating membrane before the ILV is released (PubMed:12860994, PubMed:18209100). The ESCRT machinery also functions in topologically equivalent membrane fission events, such as the terminal stages of cytokinesis (PubMed:21310966). Together with SPAST, the ESCRT-III complex promotes nuclear envelope sealing and mitotic spindle disassembly during late anaphase (PubMed:26040712). Plays a role in the endosomal sorting pathway. ESCRT-III proteins are believed to mediate the necessary vesicle extrusion and/or membrane fission activities, possibly in conjunction with the AAA ATPase VPS4. When overexpressed, membrane-assembled circular arrays of CHMP4B filaments can promote or stabilize negative curvature and outward budding. CHMP4A/B/C are required for the exosomal release of SDCBP, CD63 and syndecan (PubMed:22660413)

The "CHMP4B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CHMP4B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets